Literature DB >> 28544

Tardive dyskinesia and psychotropic drug history.

G M Simpson, E Varga, J H Lee, B Zoubok.   

Abstract

The adult population of a large mental hospital was screened for tardive dyskinesia (TD). Approximately 11% of the hospital population showed signs of TD; females and the elderly were over-represented in the TD group. A representative sample of those with TD was selected and a control (non-TD) patient was chosen to match each of the TD subjects in age, sex, length of hospitalization, diagnosis, and race. The charts of these subjects were searched for any indices of brain damage and the complete psychotropic medication history was recorded. There was no difference between the TD and controls in the amount of psychotropics ingested, in the duration of administration, in the kinds of drugs, or in the organicity history. Women as a group, however, tended to have more polypharmacy than men. The role of neuroleptics in TD is discussed as well as other possible etiological factors.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 28544     DOI: 10.1007/BF00426893

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  16 in total

1.  AN APPARENTLY IRREVERSIBLE SYNDROME OF ABNORMAL MOVEMENTS FOLLOWING PHENOTHIAZINE MEDICATION.

Authors:  R HUNTER; C J EARL; S THRONICROFT
Journal:  Proc R Soc Med       Date:  1964-08

2.  Drug variables in the etiology of tardive dyskinesia application of discriminant function analysis.

Authors:  G Gardos; J O Cole; R A La Brie
Journal:  Prog Neuropsychopharmacol       Date:  1977

Review 3.  Persistent dyskinesia.

Authors:  G E Crane
Journal:  Br J Psychiatry       Date:  1973-04       Impact factor: 9.319

4.  Tardive dyskinesia and drug therapy in geriatric patients.

Authors:  G E Crane; R A Smeets
Journal:  Arch Gen Psychiatry       Date:  1974-03

5.  Tardive dyskinesia: its relation to neuroleptic and antiparkinson drugs.

Authors:  I Turek; A A Kurland; T E Hanlon; M Bohm
Journal:  Br J Psychiatry       Date:  1972-12       Impact factor: 9.319

6.  The prevalence of tardive dyskinesias in mental hospital patients.

Authors:  W E Fann; J M Davis; D S Janowsky
Journal:  Dis Nerv Syst       Date:  1972-03

7.  The significance of brain damage in persistent oral dyskinesia.

Authors:  H Edwards
Journal:  Br J Psychiatry       Date:  1970-03       Impact factor: 9.319

8.  Extrapyramidal disorders after prolonged phenothiazine therapy.

Authors:  P F Kennedy; H I Hershon; R J McGuire
Journal:  Br J Psychiatry       Date:  1971-05       Impact factor: 9.319

9.  Comparative analysis of persistent dyskinesias of long-term usage with neuroleptics in France and in Japan.

Authors:  K Ogita; G Yagi; H Itoh
Journal:  Folia Psychiatr Neurol Jpn       Date:  1975

10.  Persistent oral dyskinesia in female mental hospital patients.

Authors:  I G Pryce; H Edwards
Journal:  Br J Psychiatry       Date:  1966-10       Impact factor: 9.319

View more
  7 in total

1.  Early dyskinesia--vulnerability.

Authors:  J O Cole; G Gardos; L A Boling; D Marby; D Haskell; P Moore
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Tardive dyskinesia in non-western countries: a review.

Authors:  A K Pandurangi; Y A Aderibigbe
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

3.  Serum neuroleptic concentrations and tardive dyskinesia.

Authors:  D V Jeste; M Linnoila; R L Wagner; R J Wyatt
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

Review 4.  Management of tardive dyskinesia: current update.

Authors:  G M Simpson; E H Pi; J J Sramek
Journal:  Drugs       Date:  1982-05       Impact factor: 9.546

5.  A cell membrane correlate of tardive dyskinesia in patients treated with phenothiazines.

Authors:  G S Zubenko; B M Cohen
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

6.  Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug.

Authors:  J A Severson; H E Robinson; G M Simpson
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Cytotoxic effects of neuroleptic drugs.

Authors:  W H Munyon; R Salo; D F Briones
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.